Aims and Scope
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058.
Key Metrics
5.6
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
52
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
Q1
Pharmacology
SJR
- Q2 Pharmacology
- Q1 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.8
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Immune checkpoint inhibitors
- Epidermolysis bullosa
- Tumor microenvironment
- Major depressive disorder
- Synthetic drugs
- Cirrhosis
- Chronic myelomonocytic leukemia
- Adrenocortical carcinoma
- Cytotoxic chemotherapy
- Standard of care
- Antibody therapy
- Nonalcoholic fatty liver disease
- Imatinib
- Sunitinib
- Treatment options
- Regorafenib
- Immunotherapy
Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Expert Opinion on Emerging Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
- 14 Apr 24
- Expert Opinion on Emerging Drugs
-
Full paper
Evolving role of viadisc for chronic low back and discogenic pain: a narrative review
- 13 Apr 24
- Expert Opinion on Emerging Drugs
-
Full paper
Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update
- 13 Apr 24
- Expert Opinion on Emerging Drugs
-
Full paper
Emerging drugs for the treatment of herpetic keratitis
- 13 Apr 24
- Expert Opinion on Emerging Drugs
-
Full paper
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma
- 12 Apr 24
- Expert Opinion on Emerging Drugs
-
Full paper
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
- 7 Apr 24
- Expert Opinion on Emerging Drugs
Scite analysis
Powered by scite_
1k articles received 12.4k citations see all
- 93 Supporting
- 11,895 Mentioning
- 10 Contrasting
Editorial notices
- 1 Retractions
- 0 Withdrawals
- 3 Corrections
- 3 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
29%
4 to 6 months
55%
7 to 9 months
10%
Above 9 months
6%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has Expert Opinion on Emerging Drugs been actively publishing?
Expert Opinion on Emerging Drugs has been in operation since 2001 till date.
What is the publishing frequency of Expert Opinion on Emerging Drugs ?
Expert Opinion on Emerging Drugs published with a Quarterly frequency.
How many articles did Expert Opinion on Emerging Drugs publish last years ?
In 2023, Expert Opinion on Emerging Drugs published 29 articles.
What is the eISSN & pISSN for Expert Opinion on Emerging Drugs ?
For Expert Opinion on Emerging Drugs,eISSN is 1744-7623 and pISSN is1472-8214.
What is Citescore for Expert Opinion on Emerging Drugs ?
Citescore for Expert Opinion on Emerging Drugs is 5.6.
What is H index for Expert Opinion on Emerging Drugs ?
H index for Expert Opinion on Emerging Drugs is 52.
What is SNIP score for Expert Opinion on Emerging Drugs ?
SNIP score for Expert Opinion on Emerging Drugs is 0.8.
What is the SJR for Expert Opinion on Emerging Drugs ?
SJR for Expert Opinion on Emerging Drugs is Q1.
Who is the publisher of Expert Opinion on Emerging Drugs ?
TAYLOR & FRANCIS LTD is the publisher of Expert Opinion on Emerging Drugs.